The company said Reported Sales for Q3 2026 rose 5.9% to $25,399 million, while net earnings of $210 million (diluted EPS of $0.09) fell 95.9% and 95.8%, respectively, from $5,152 million (EPS of $2.12) a year earlier.

1. 01

   The company said Reported Sales for Q3 2026 rose 5.9% to $25,399 million, while net earnings of $210 million (diluted EPS of $0.09) fell 95.9% and 95.8%, respectively, from $5,152 million (EPS of $2.12) a year earlier.

2. 02

   The company said diluted EPS of $0.09 for Q3 reflects a one-time special charge for the proposed talc litigation resolution, the acquisition of Firefly Bio, Inc., and the strategic collaboration with Sail Biomedicines. It said adjusted EPS of $2.59 also reflects the impact of these M&A deals.

3. 03

   Johnson & Johnson said Innovative Medicine sales rose 7.7% to $16,757 million on a reported basis for Q3, while MedTech sales rose 2.5% to $8,642 million. The company said STELARA had an impact of about 690 basis points on Innovative Medicine growth.

4. 04

   Johnson & Johnson set its full-year 2026 adjusted EPS outlook at $11.05 to $11.15 (midpoint $11.10), compared with its prior outlook from July 29, 2026 of $10.96 to $11.11 (midpoint $11.04). Estimated reported sales are $101.0B to $101.4B (midpoint $101.2B), and the Euro average rate of $1.15 is for illustrative purposes only.

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.